Coffee improves survival in metastatic colon cancer

Drinking two to three cups of coffee a day is associated with increased survival in patients with metastatic colorectal cancer, as well as a lower risk of cancer progressing, notes a study published in “JAMA Oncology.”

The findings, based on data from a large study, are similar to previous studies showing a relationship between regular coffee consumption and better outcomes in patients with non-metastatic colorectal cancer.

Researchers have seen that 1,171 patients Treated for metastatic colorectal cancer, those who reported consuming two to three cups of coffee a day were more likely to live longer and had more time before their disease worsened than those who did not drink coffee. Participants who drank large amounts of coffee – more than four cups a day – had even greater benefit. The benefits were obtained with both caffeinated and decaffeinated coffee.

The findings allowed the researchers to establish an association, but not a cause-and-effect relationship, between coffee consumption and reduced risk of cancer progression and death among study participants.

The benefits were obtained with both caffeinated and decaffeinated coffee.

The study does not provide sufficient reason to recommend daily coffee consumption, or increased intake, to people with advanced or metastatic colorectal cancer, the researchers say.

“It is known that some compounds in coffee have antioxidant, anti-inflammatory, and other properties that can be active against cancer,” he says. Chen Yuan, from high school Dana-Farber, co-author of the study with Christopher Mackintosh of the Mayo Clinic School of Medicine (USA). ‘Epidemiological studies have found that higher coffee intake was associated with better survival in patients with stage 3 colon cancer, but the relationship between coffee consumption and survival in patients with metastatic forms of the disease is unknown ».

Those who consumed more than four cups per day had an even greater benefit.

The work was based on data from the Alliance / SWOG study 80405, a clinical trial of phase III comparing the addition of cetuximab and / or bevacizumab to standard chemotherapy in patients with previously untreated, locally advanced, or metastatic colorectal cancer. As part of the trial, participants reported their dietary intake, including coffee consumption, in a questionnaire at the time of enrollment. The researchers correlated these data with information about the course of cancer after treatment.

They found that participants who drank two to three cups of coffee a day had a lower risk of death and cancer progression compared to those who did not drink coffee. Those who consumed more than four cups per day had an even greater benefit.

“Although it is premature to recommend a high intake of coffee as a potential treatment for colorectal cancer, our study suggests that drinking coffee is not harmful and may be potentially beneficial,” he notes Kimmie ng, lead author of the study.

Design by NewsLax